Aastrom Biosciences to Present at RBC Capital Markets Healthcare Conference
08 December 2006 - 8:00AM
PR Newswire (US)
ANN ARBOR, Mich., Dec. 7 /PRNewswire-FirstCall/ -- Aastrom
Biosciences, Inc. (NASDAQ:ASTM), a clinical development stage
company focused on the use of autologous cells for regenerative
medicine, today announced that George W. Dunbar, President and
Chief Executive Officer will participate on the Tissue, Blood &
Bone: Advanced Implants & Surgical Tools panel on Wednesday,
December 13, 2006 at 3:30 p.m. (EST) as part of the 2006 RBC
Capital Markets Healthcare Conference. The conference will be held
December 13-14th at the Westin New York at Times Square Hotel in
New York City. (Logo:
http://www.newscom.com/cgi-bin/prnh/20060302/NETH028LOGO ) A live
audio-only webcast of Aastrom's panel presentation can be accessed
by logging onto the web at
http://www.wsw.com/webcast/rbc62/panel16. A replay of the
audio-only panel presentation will be archived for 30 days at the
same Internet site. About Aastrom Biosciences, Inc. Aastrom
Biosciences, Inc. (NASDAQ:ASTM) is developing autologous cell
products for the repair or regeneration of multiple human tissues,
based on its proprietary Tissue Repair Cell (TRC) technology.
Aastrom's TRC-based products are a unique cell mixture containing
stem and progenitor cell populations, produced from a small amount
of bone marrow taken from the patient. TRC-based products have been
used in over 230 patients, and are currently in clinical trials for
bone regeneration (long bone fractures and spine fusion) and
vascular regeneration (critical limb ischemia) applications.
Aastrom has reported positive interim clinical trial results for
TRCs suggesting both the clinical safety and the ability of TRCs to
promote healing in bone regeneration applications. The Company's
proprietary TRCs received an Orphan Drug Designation from the U.S.
Food and Drug Administration (FDA) for use in the treatment of
osteonecrosis of the femoral head. In addition, Aastrom is
developing plans for TRC-based therapies to address cardiac and
neural regeneration indications. For more information, visit
Aastrom's website at http://www.aastrom.com/ . This document
contains forward-looking statements, including without limitation,
statements regarding product development objectives, market
development plans, and potential advantages and applications of
Tissue Repair Cells, which involve certain risks and uncertainties.
The forward-looking statements are also identified through use of
the words "plans," and other words of similar meaning. Actual
results may differ significantly from the expectations contained in
the forward-looking statements. Among the factors that may result
in differences are the results obtained from clinical trial
activities, regulatory approval requirements, and the availability
of resources. These and other significant factors are discussed in
greater detail in Aastrom's Annual Report on Form 10-K and other
filings with the Securities and Exchange Commission. CONTACTS: Kris
M. Maly Cameron Associates Investor Relations Department Kevin
McGrath Aastrom Biosciences, Inc. Phone: (212) 245-4577 Phone:
(734) 930-5777 Deanne Eagle (Media) Phone: (212) 554-5463
http://www.newscom.com/cgi-bin/prnh/20060302/NETH028LOGO
http://photoarchive.ap.org/ DATASOURCE: Aastrom Biosciences, Inc.
CONTACT: Kris M. Maly, Investor Relations Department of Aastrom
Biosciences, Inc., +1-734-930-5777; Kevin McGrath, +1-212-245-4577,
or Deanne Eagle (Media), +1-212-554-5463, both of Cameron
Associates Web site: http://www.aastrom.com/
Copyright
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Sep 2023 to Sep 2024